GLP-1 receptor ligands are famous as metabolic drugs. US12115225B2 - "GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof," issued October 15, 2024 to AstraZeneca AB - uses one for something else entirely: as a delivery address for an oligonucleotide.

The inventive limitation is the repurposing of the ligand, and claim 1 states it as a method with three required components. The method modulates the expression of a nucleic acid target in a pancreatic beta-islet cell that expresses GLP-1 receptor on its surface, by contacting that cell with a compound comprising: a modified oligonucleotide; a GLP-1 peptide conjugate moiety capable of binding the GLP-1 receptor; and a conjugate linker joining the two. The oligonucleotide has a nucleobase sequence complementary to the target, so the GLP-1 ligand acts as a homing device that delivers the RNA cargo to GLP-1R-bearing cells - the pancreatic beta-islet cell named in the claim - rather than as a receptor agonist producing a metabolic effect. That cell-type specificity is a real limitation, not background: claim 1 is anchored to the beta-islet cell.

"The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor."- U.S. Patent No. 12,115,225 source

The dependent claims disclose the oligonucleotide engineering in detail. Claim 4 sets the length at 15 to 30 linked nucleosides; claim 5 requires at least one modified linkage, sugar, or nucleobase; and claim 6 recites the classic gapmer architecture - a central gap segment of linked deoxynucleosides flanked by 5' and 3' wing segments whose nucleosides carry modified sugars. The gapmer is the disclosed mechanism for an antisense oligonucleotide that recruits RNase H to cleave its target while resisting degradation. Claim 8 sizes the GLP-1 peptide moiety at 8 to 50 amino acids; claims 11 and 12 give the exact peptide sequence (His-Aib-Glu-Gly-Thr-Phe... a GLP-1 analog bearing aminoisobutyric acid at position 2, SEQ ID NO: 22); and claim 9 enumerates linker chemistries (disulfide, cysteine, PEG, triethylene glycol, phosphate). This is an oligonucleotide-delivery claim wearing a defined GLP-1 ligand as its targeting tag.

The CPC profile makes the dual chemistry visible: A61K 47/6425 and A61K 47/65 (targeting-conjugate chemistry), A61K 31/713 (siRNA), C12N 15/111 (the oligonucleotide), with the dense C12N 2310/3xx series describing the oligonucleotide's chemical modifications. The signature is two chemistries - peptide-ligand and modified oligonucleotide - fused in one claimed compound.

Why does the targeting role decide scope? Because the prior art separately holds GLP-1R ligands (as drugs) and silencing or antisense oligonucleotides. The claimed novelty is the conjugate that uses the ligand to deliver the oligonucleotide to a chosen cell population - here, the GLP-1R-expressing beta-islet cell. A competitor using a different targeting moiety, using the GLP-1 ligand as a conventional agonist, or directing the oligonucleotide to cells outside the claimed population may fall outside claim 1 as written. The Aib-modified peptide sequence and the gapmer architecture are the kinds of specific disclosures that both narrow the claim and make it defensible.

The gapmer architecture in claim 6 is worth unpacking, because it is the disclosed engine of the oligonucleotide's action. A gapmer is a chimeric oligonucleotide with a central "gap" of DNA-like (deoxynucleoside) chemistry flanked by two "wings" of sugar-modified nucleosides. When the oligonucleotide hybridizes to its complementary RNA target, the DNA gap forms an RNA:DNA duplex that recruits the cellular enzyme RNase H to cleave the target, while the modified wings resist nuclease degradation and raise binding affinity. Claim 6 recites precisely this layout - a gap segment of linked deoxynucleosides positioned immediately between 5' and 3' wing segments whose nucleosides carry modified sugars - which is why the claim covers an antisense, RNase-H-recruiting mechanism rather than a double-stranded siRNA. Claim 7 confirming the oligonucleotide is single-stranded reinforces that reading.

The peptide half is equally specified. Claims 11 and 12 give the GLP-1 conjugate moiety as an exact sequence (His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-..., SEQ ID NO: 22) carrying aminoisobutyric acid at position 2 - the same Aib substitution used in long-acting GLP-1 analogs to resist DPP-4 cleavage. Here, though, the peptide's job is not pharmacodynamic; it is to bind the GLP-1 receptor as a homing tag so the receptor's internalization carries the oligonucleotide cargo into the cell. Claim 9's linker menu (disulfide, cysteine, penicillamine, hexylamino, PEG, triethylene glycol, phosphate) and claim 10's depicted linker chemistry define how the two moieties are joined and, by implication, how the cargo is released intracellularly.

For claim construction, the combination of a cell-type anchor (the pancreatic beta-islet cell of claim 1), a defined targeting peptide, a defined gapmer oligonucleotide, and a defined linker means infringement turns on a stack of specific structural and contextual facts. The claim is not "deliver an oligonucleotide with a GLP-1 ligand" in the abstract; it is this construct, modulating a target in this cell type, with this delivery chemistry - a narrow, defensible species at the seam of two estates.

A final construction point: claim 1 is framed as a method of modulating expression of a nucleic acid target in the named cell, with claim 2 specifying that contacting the cell inhibits expression and claim 3 enumerating the target species (pre-mRNA, mRNA, non-coding RNA, or miRNA). That framing matters because it ties the claim to a molecular outcome - target knockdown in a GLP-1R-expressing cell - rather than to any downstream phenotype. For a teardown, the consequence is that the claim is anchored at the level of the delivered cargo and its action on a nucleic-acid target, which keeps it firmly in device-and-mechanism territory: the patentable contribution is the targeted-delivery construct and what it does to RNA in the cell, not a therapeutic result.

For the landscape, this grant sits at the intersection of the metabolic-peptide estate and the oligonucleotide-delivery estate - a convergence that turns a well-known drug class into a delivery technology. It illustrates why freedom-to-operate analysis cannot silo by therapeutic area: a GLP-1 ligand can show up as the targeting arm of an RNA drug, pulling two previously separate IP fields into one claim, and any program building ligand-targeted oligonucleotides has to read both estates together.